Biosimilars Are Making Inroads In U.S., But It’s Still A Bumpy Ride

Biosimilars offer clinically effective treatment alternatives to branded reference drugs at a lower cost. These products are making inroads in the United States, but it’s still a bumpy ride. Though we’ve recently observed some improvement in the situation, market entry and uptake in the U.S. still consistently lag behind Europe.